Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31312499 | 1.00 | TSHR (0.64) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL2873685 | 0.83 | VCAM1 (0.56) | TSHRMAPK1TDP1S100A4TRPV1 | |
| SCHEMBL30955236 | 0.83 | VCAM1 (0.56) | TSHRMAPK1TDP1S100A4TRPV1 | |
| SCHEMBL4609255 | 0.81 | PDE7A (0.72) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL4608336 | 0.81 | MMP1 (0.56) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL1561802 | 0.80 | TSHR (0.56) | TSHRMAPK1TDP1S100A4TRPV1 | |
| SCHEMBL31281371 | 0.79 | TSHR (0.67) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL359179 | 0.79 | TSHR (0.67) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL29398960 | 0.78 | TSHR (1.00) | TSHRMAPK1CA1CA2MMP1 | |
| SCHEMBL165733 | 0.78 | CYP19A1 (0.49) | TSHRMAPK1TDP1PDE7AS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107383076-A | A kind of synthetic method of the chlorophenylboronic acid pinacol ester of 3 amino 4 | 吉尔生化（上海）有限公司 | 2017-11-24 | — | — | CN | claimed |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-4457230-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-118414336-A | Degradation of Bruton Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023027203-A1 | LUMINESCENT MATERIAL FOR ORGANIC ELECTROLUMINESCENT DEVICE, ORGANIC ELECTROLUMINESCENT DEVICE USING SAME, AND MATERIAL FOR ORGANIC ELECTROLUMINESCENT DEVICE | 최돈수 | 2023-03-02 | — | — | WO | disclosed |
| US-10703762-B2 | Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus | IDEMITSU KOSAN CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| CN-110305018-A | A kind of preparation method of the bromo- 2- fluoronitrobenzene of 3- | 浙江普洛家园药业有限公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-109369641-A | A kind of organic electroluminescence device compound | 韩国高智株式会社 | 2019-02-22 | — | — | CN | disclosed |
| CN-109071411-A | The method for manufacturing nitrobenzene compound | 组合化学工业株式会社 | 2018-12-21 | — | — | CN | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| CN-1434828-A | Novel bisaminophosphonate prodrugs | METABASIS THERAPEUTICS INC (US) | 2003-08-06 | — | — | CN | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| US-5750789-A | FROM CORRESPONDING DIAMINE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-05-12 | — | — | US | disclosed |
| WO-1997013767-A1 | HETEROCYCLICALLY-SUBSTITUTED 1-INDOLE CARBOXAMIDES AS CYCLO-OXYGENASE-2 INHIBITORS | CHEMISCH PHARMAZEUTISCHE FORSCHUNGSGESELLSCHAFT MBH (AT) | 1997-04-17 | — | — | WO | disclosed |
| US-5498687-A | Unsaturated imide compounds containing alicyclic structure, process for producing the same and intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5444165-A | Reacting diamino compound with unsaturated dicarboxylic anhydride to form amic acid intermediate, catalytic dehydration-ring closing; solvent soluble, low water absorption and flexibility | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-08-22 | — | — | US | disclosed |
| US-5326881-A | Polymers with good heat resistance, good flexibility and low water absorption | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0595230-A1 | Unsaturated imide compounds containing alicyclic structure | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | TSHR 3350/4885MAPK1 434/4885CA1 1683/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | TSHR 3215/4885MAPK1 926/4885CA1 2181/4885 |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | TSHR 2917/4885MAPK1 1826/4885CA1 4789/4885 |
| US-10703762-B2 | Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus | PIEZO1, OR10J3, EPCAM | TSHR 4280/4885MAPK1 977/4885CA1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.